Clinical Trial

Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer

Study acronym: DEHIM_CCRT
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the efficacy and safety of hypofractionated intensity-modulated radiation therapy (IMRT) combined with concurrent chemotherapy in patients with cervical cancer. Conventional treatment usually requires 7-8 weeks, which increases the risk of toxicities and treatment delays. This trial seeks to shorten the overall treatment time while maintaining non-inferior tumor response and survival outcomes compared to standard therapy. The primary endpoint is tumor volume reduction rate (TVRR) assessed by pelvic MRI at 1 month after treatment. Secondary endpoints include 3-year local recurrence rate, progression-free survival, and incidence of acute and late grade ≥3 toxicities. The results of this study are expected to contribute to establishing an optimal treatment strategy for cervical cancer.
Trial Details
NCT Number NCT07439497
Lead Sponsor Samsung Medical Center
Conditions Cervical Cancer
Enrollment 34 participants
Start Date 2025-12-09
Primary Completion 2026-05-30 (estimated)
Study Completion 2028-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-27